Hospital Pharmacists’ Intervention In Access To Innovative Therapies – Opportunities And Strategies: A Mixed-Method Design-Reference-Cited by-同舟云学术

Hospital Pharmacists’ Intervention In Access To Innovative Therapies – Opportunities And Strategies: A Mixed-Method Design

Published:2024-03-29 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Coelho Helena¹,Fraga Susana²,Lopes Teresa¹,Fraga João¹,Santos Susana³,Ferro Margarida⁴

Affiliation:

1. Sociedade Portuguesa de Farmacêuticos dos Cuidados de Saúde

2. Sociedade Portuguesa de Farmacêuticos dos Cuidados de Saúde, Coimbra, Portugal

3. Janssen-Cilag Farmacêutica, LDA

4. Moai Consulting, LDA

Abstract

BACKGROUND: Hospital Pharmacists (HP) intervene in multiple activities to ensure the patient access to innovative therapies in hospitals, including decision-making process. AIM: To identify opportunities and strategies that leverage the intervention of HP to improve the access pathway to innovative therapies in hospitals of these therapies. METHODS: After semi-structured interviews, a survey was implemented targeting Portuguese HP, followed by an expert panel with HP (n=12) to reach a consensus. Data was collected between October 2021 and March 2022. RESULTS: 58 HP answered the survey. Even though the most important activities identified were related to HP’s support in the decision-making for approval of innovative therapies, it was consensual that there are opportunities for optimizing this process. The expert panel proposed 5 strategic actions focusing on access to legal information about innovative therapies, the approval process, and enhancing collaboration among all stakeholders. CONCLUSION: HP’s intervention in the decision-making process is essential in the therapeutic innovation access pathway. Therefore, it is important to implement strategies to make the process faster, more informative, and efficient.

Publisher

Research Square Platform LLC

Reference15 articles.

1. Lichtenberg, F.R. (2022). The effect of pharmaceutical innovation on longevity: Evidence from the U.S. and 26 high-income countries. Econ Hum Biol 46. https://doi.org/10.1016/j.ehb.2022.101124.

2. Barua, B., Westcott, W., and Vo, V.N. (2021). Timely Access to New Pharmaceuticals in Canada, the United States, and the European Union. https://www.fraserinstitute.org/studies/timely-access-to-new-pharmaceuticals-in-canada-the-united-states-and-the-european-union.

3. Medlinskiene, K., Tomlinson, J., Marques, I., et al. (2021). Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review. BMC Health Serv Res 21. https://doi.org/10.1186/s12913-021-07196-4.

4. ASHP Guidelines on the Pharmacy and Therapeutics Committee and the Formulary System;Ciccarello C;Am J Health Syst Pharm,2021

5. J Manag Care Spec Pharm (2020). AMCP Partnership Forum: Principles for Sound Pharmacy and Therapeutics (P&T) Committee Practices: What’s Next? J Manag Care Spec Pharm 26. https://doi.org/10.18553/jmcp.2020.26.1.48.